Skip to main content

Table 4 A comparison between lean participants (normal BMI; n = 50) with and without double diabetes. Data are presented as median and interquartile range (IQ), and as percentages for frequencies. ACEI, angiotensin-converting-enzyme inhibitors; ARB, Angiotensin II receptor blockers; BMI: body mass index; eGDR: estimated glucose disposal rate; HbA1c: haemoglobin A1c. *p-value < 0.05

From: The association between overweight/obesity and double diabetes in adults with type 1 diabetes; a cross-sectional study

Selected study cohort characteristics

Double diabetes in participant with normal BMI

No (n = 36)

Yes (n = 14)

Age at clinic (years)

24.5 (21.0-35.8)

39.0 (23.0-63.8)*

Age at diagnosis (years)

18.0 (11.0-24.5)

17.0 (11.3–51.8)

Diabetes duration (years)

9.0 (2.0–17.0)

9.5 (5.8–18.8)

Female [n (%)]

16 (44)

6 (43)

Body weight (kg)

63.4 (60.3–73.1)

67.3 (59.6–75.0)

BMI (kg/m2)

22.6 (20.1–23.5)

23.2 (22.0-24.6)

HbA1c (mmol/mol)

65.0 (55.0-74.8)

88.5 (70.8-105.3)*

Total Insulin dose (units)

42.0 (30.6–50.3)

41.5 (31.5–58.3)

Insulin dose (unit/kg/day)

0.65 (0.47–0.77)

0.68 (0.50–0.76)

Total Cholesterol (mmol/L)

3.8 (3.4–4.9)

4.3 (3.7–5.4)

Triglyceride (mmol/L)

0.9 (0.7–1.3)

1.3 (0.8–1.6)

HDL Cholesterol (mmol/L)

1.6 (1.3–1.9)

1.6 (1.4-2.0)

LDL Cholesterol (mmol/L)

2.0 (1.6–2.5)

2.2 (1.9-3.0)

Hypertension, [n (%)]

0 (0)

4 (29)*

Statins [n (%)]

7 (19)

4 (29)

ACEI/ARB [n (%)]

2 (6)

2 (14)

Metformin [n (%)]

4 (11)

3 (21)

Microalbuminuria, [n (%)]

0 (0)

5 (36)*

eGDR

9.0 (8.6–10.0)

7.1 (5.6–7.4)*